{"id":191,"date":"2023-09-07T19:35:07","date_gmt":"2023-09-07T19:35:07","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=191"},"modified":"2026-04-16T19:26:45","modified_gmt":"2026-04-16T19:26:45","slug":"milestones","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/milestones\/","title":{"rendered":"Milestones"},"content":{"rendered":"\n
<\/div>\n\n\n\n

About<\/a><\/p>\n\n\n\n

Milestones<\/h1>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Mar 2026<\/h3>\n<\/div>\n\n\n\n
\n

First European patient randomized in global GALAXY GA Phase 2 clinical trial<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Feb 2026<\/h3>\n<\/div>\n\n\n\n
\n

First Canadian patient randomized in global GALAXY GA Phase 2 clinical trial<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Oct 2025<\/h3>\n<\/div>\n\n\n\n
\n

First patient randomized in global GALAXY GA Phase 2 clinical trial<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Aug 2025<\/h3>\n<\/div>\n\n\n\n
\n

Received approvals from WHO and USAN Council establishing \u201cxelafaslatide\u201d as nonproprietary name for ONL1204 Ophthalmic Solution<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Sep 2024<\/h3>\n<\/div>\n\n\n\n
\n

Series D financing closes<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Apr 2024<\/h3>\n<\/div>\n\n\n\n
\n

OAG Phase 1b \u2013 Last patient, last visit completed<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Feb 2024<\/h3>\n<\/div>\n\n\n\n
\n

GA Phase 1b \u2013 Last patient, last visit completed<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Aug 2023<\/h3>\n<\/div>\n\n\n\n
\n

Series C financing \u2013 Tranche 2 closes<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Aug 2023<\/h3>\n<\/div>\n\n\n\n
\n

Enrollment completed for Phase 2 Retinal Detachment study<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Apr 2023<\/h3>\n<\/div>\n\n\n\n
\n

First patient dosed in Phase 2 Retinal Detachment study<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Mar 2023<\/h3>\n<\/div>\n\n\n\n
\n

Series C financing \u2013 Tranche 1 closes<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Jan 2023<\/h3>\n<\/div>\n\n\n\n
\n

IND open for ONL1204 Ophthalmic Solution (Phase 2 Retinal Detachment study)<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Dec 2022<\/h2>\n<\/div>\n\n\n\n
\n

IND filed for ONL1204 Ophthalmic Solution<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Nov 2022<\/h2>\n<\/div>\n\n\n\n
\n

RRD Phase 1 study completed<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Nov 2022<\/h2>\n<\/div>\n\n\n\n
\n

GA Phase 1b – Open Label\/Dose escalation portion completed<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

May 2022<\/h2>\n<\/div>\n\n\n\n
\n

First patient dosed in OAG Phase 1b clinical trial<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Jan 2022<\/h2>\n<\/div>\n\n\n\n
\n

Series B financing – Tranche 2 closes<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Oct 2021<\/h2>\n<\/div>\n\n\n\n
\n

First patient dosed in GA Phase 1b clinical trial (dose escalation phase)<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Jul 2021<\/h2>\n<\/div>\n\n\n\n
\n

First patient screened in GA Phase 1b clinical trial<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

May 2021<\/h2>\n<\/div>\n\n\n\n
\n

Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 3 (100 \u00b5g)<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Jan 2021<\/h2>\n<\/div>\n\n\n\n
\n

Australian regulatory approval for the Phase 1b study in patients with GA secondary to AMD<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Dec 2020<\/h2>\n<\/div>\n\n\n\n
\n

Series B financing – Tranche 1 closes<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Nov 2020<\/h2>\n<\/div>\n\n\n\n
\n

Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 2 (50 \u00b5g)<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Mar 2020<\/h2>\n<\/div>\n\n\n\n
\n

Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 1 (25 \u00b5g)<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Dec 2019<\/h2>\n<\/div>\n\n\n\n
\n

ONL1204 patent issued in US<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Oct 2019<\/h2>\n<\/div>\n\n\n\n
\n

First patient dosed, first in human clinical trial in retinal detachment<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Oct 2019<\/h2>\n<\/div>\n\n\n\n
\n

Australian regulatory approval for Phase 1 study in patients with retinal detachment<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Aug 2019<\/h2>\n<\/div>\n\n\n\n
\n

Convertible note financing<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Sep 2018<\/h2>\n<\/div>\n\n\n\n
\n

Convertible note financing<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

May 2017<\/h2>\n<\/div>\n\n\n\n
\n

Series A financing<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Feb 2011<\/h2>\n<\/div>\n\n\n\n
\n

Company formation<\/p>\n<\/div>\n<\/div>\n\n\n\n